Jason P Rhodes Net Worth

The estimated Net Worth of Jason P Rhodes is at least 108 百万$ dollars as of 1 March 2024. Jason Rhodes owns over 46,534 units of Dyne Therapeutics stock worth over 27,624,849$ and over the last 11 years Jason sold DYN stock worth over 80,136,514$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Jason Rhodes DYN stock SEC Form 4 insiders trading

Jason has made over 26 trades of the Dyne Therapeutics stock since 2014, according to the Form 4 filled with the SEC. Most recently Jason sold 46,534 units of DYN stock worth 1,398,347$ on 1 March 2024.

The largest trade Jason's ever made was buying 1,100,000 units of Dyne Therapeutics stock on 18 November 2019 worth over 14,971,000$. On average, Jason trades about 122,018 units every 84 days since 2013. As of 1 March 2024 Jason still owns at least 847,388 units of Dyne Therapeutics stock.

You can see the complete history of Jason Rhodes stock trades at the bottom of the page.

What's Jason Rhodes's mailing address?

Jason's mailing address filed with the SEC is C/O GENERATION BIO CO., 301 BINNEY ST, , CAMBRIDGE, MA, 02142.

Insiders trading at Dyne Therapeutics

Over the last 4 years, insiders at Dyne Therapeutics have traded over 197,573,300$ worth of Dyne Therapeutics stock and bought 5,790,447 units worth 92,382,301$ . The most active insiders traders include Capital Management, L.P.Kol...、Jason P Rhodes、Dirk Kersten. On average, Dyne Therapeutics executives and independent directors trade stock every 12 days with the average trade being worth of 3,566,016$. The most recent stock trade was executed by Oxana Beskrovnaya on 11 September 2024, trading 2,161 units of DYN stock currently worth 68,914$.

What does Dyne Therapeutics do?

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

Complete history of Jason Rhodes stock trades at Epizyme Inc、Replimune Inc、Generation Bio Co、Dyne Therapeutics

Dyne Therapeutics executives and stock owners

Dyne Therapeutics executives and other stock owners filed with the SEC include:

• Dewei Qiao,
  General Manager, Executive Director
• Shengyong Hu,
  Chief Financial Officer, Executive Director
• Joshua T. Brumm,
  CEO, Pres & Director
• Dr. Romesh Subramanian Ph.D.,
  Co-Founder & Advisor
• Susanna Gatti High M.B.A.,
  Chief Operating Officer
• Lanjun Xie,
  Non-Executive Independent Director
• Yuezhou Ou,
  Independent Non-Executive Director
• Jie Fu,
  Non-Executive Independent Director
• Shuguang Liu,
  Non-Executive Director
• Sunning Cheng,
  Non-Executive Director
• Jinjun Cao,
  Non-Executive Director
• Wing Yan Yuen,
  Company Secretary
• Shuguang Zhu,
  Deputy General Manager and Secretary of the Board
• Yong Zhang,
  Deputy General Manager
• Jianzhong Huang,
  Deputy General Manager
• Yan Cheng,
  Deputy General Manager
• Jun Zhi,
  Non-Executive Chairman of the Board
• Kate Mitchell,
  VP & Head of HR
• Richard William Scalzo M.B.A.,
  Sr. VP, Head of Fin. & Admin. and Treasurer
• Dr. Thomas-Christian Mix M.D., M.S.,
  Sr. VP of Clinical Devel.
• Richard William Scalzo,
  VP of Accounting & Admin. and Treasurer
• Daniel Wilson,
  VP & Head of Intellectual Property
• Debra Feldman,
  VP & Head of Regulatory Affairs
• Dr. Thomas-Christian Mix M.D.,
  Sr. VP of Clinical Devel.
• Dr. Oxana Beskrovnaya Ph.D.,
  Chief Scientific Officer
• Amy Reilly,
  VP of Corp. Communications & Investor Relations
• Richard Scalzo,
  VP of Accounting & Admin. and Treasurer
• Gene Kim,
  VP of Fin.
• Johanna Friedl Naderer,
  Chief Commercial Officer
• Lawrence Otto Klein,
  Director
• Capital Fund Iv Cooperatief...,
  10% owner
• Global Management Lp Logos,
  10% owner
• Dirk Kersten,
  
• Venture Fund Xi, L.P.Atlas ...,
  
• Romesh Subramanian,
  Chief Scientific Officer
• Susanna Gatti High,
  Chief Operating Officer
• Douglas Kerr,
  Chief Medical Officer
• Edward Hurwitz,
  
• Carlo Incerti,
  
• David Charles Lubner,
  
• Bioventures 2018, L.P.Mpm B...,
  
• Venture Fund Xi, L.P.Atlas ...,
  
• Capital Management, L.P.Kol...,
  
• Biomedical Innovation Maste...,
  10% owner
• Jason P Rhodes,
  
• Ventures, Llc Cure Duchenne,
  10% owner
• Manager Ii, Llc Vida Ventur...,
  
• Catherine Stehman Breen,
  
• Venture Opportunity Fund Ii...,
  
• Venture Fund Xi, L.P. Atlas,
  10% owner
• Venture Fund Xi, L.P.Atlas ...,
  
• John Cox,
  CEO & President
• Wildon Farwell,
  Chief Medical Officer
• Jonathan Mc Neill,
  Chief Business Officer
• Richard William Scalzo,
  SVP, Head of Finance & Admin.
• Joshua T Brumm,
  CEO & President
• Oxana Beskrovnaya,
  Chief Scientific Officer
• Venture Opportunity Fund I,...,